The United States Food and Drug Administration (USFDA) has given Zydus Lifesciences the go-ahead to produce and sell the USP Estradiol Transdermal System, 0.014 mg/day (weekly) (USRLD: Menostar ® Transdermal System). The prevention of postmenopausal osteoporosis is indicated by the estradiol transdermal system. The group’s formulation manufacturing facility in Moraiya, Ahmedabad, will produce the medication (India). Sales of the Estradiol Transdermal System USP, 0.014 mg/day (weekly), totaled USD 1.9 million in the United States each year (IQVIA MAT Feb. 2023).
Shopping Cart